ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Vivek Subbiah et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.